The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial. On November 21, 2025, the FDA approved pembrolizumab (Keytruda) and pembrolizumab and berahyaluronidase alfa-pmph ...
YOLT-203 is an investigational gene-editing therapy for PH1, aiming to reduce oxalate overproduction by deactivating glycolate oxidase. The pivotal trial will assess YOLT-203's safety and efficacy in ...
"Based on the code description, we recommend basing the code selection on the documentation and the effort required to complete the service, and not the number of foreign bodies removed from the ...
Celeste Kirschner, CAE, MHSA, outlines the most pressing challenges facing independent urology practices today. "I think MRI has really been perhaps the most transformative development in the realm of ...
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...
Cycling has multiple benefits, and steps can be taken to prevent genitourinary injury. Bicycling across the globe is increasing as a means of exercise and transportation. Clinicians need to be ...
Experts weigh in on whether the combined technologies could be the future power couple of prostate cancer diagnosis. Prostate-specific membrane antigen (PSMA) and multiparametric magnetic resonance ...
LiSWT and PRP independently and combined significantly improved IIEF scores in ED treatment compared to control therapy. LiSWT was the most effective standalone treatment, with a mean IIEF score ...
BCG plus mitomycin demonstrated similar efficacy and safety to BCG alone, with fewer treatment discontinuations and reduced BCG doses in NMIBC patients. The combination therapy showed a 40% reduction ...
Although low, men experienced a higher risk for erectile dysfunction and hypogonadism after being prescribed semaglutide for weight loss; however, further questions remain. Non-diabetic men treated ...
Dr Hamstra describes the three FDA-approved rectal spacers SpaceOAR, Barrigel, and BioProtect, noting differences in placement technique, advantages, potential risks, and the need for long-term ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback